Clinical trials: CTLA-4
Myocarditis, Cardiac Complication
Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions
Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events (irAEs) on the cardio-vascular system. This study investigates reports of cardio-vascular toxicity with treatment including anti-PD1…
- Trial name
- RAFALE (NCT03387540)
- Testing
- ICI
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Rheumatoid Arthritis, Myocardial Inflammation
Effects of Abatacept on Myocarditis in Rheumatoid Arthritis
This study aims to evaluate the effects of abatacept, a CTLA4-Ig fusion protein that binds cluster of differentiation antigen 80 (CD80)/86 (B7-1/B7-2), on subclinical myocarditis in rheumatoid arthritis (RA) through its effect on…
- Trial name
- AMiRA (NCT03619876)
- Testing
- Abatacept, Adalimumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
Solid Tumor Cancer
A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors
This is a Phase I, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific PD-1/CTLA-4/VEGF Antibody GB268 in Participants with Advanced Solid Tumors.
- Trial name
- NCT06934616
- Testing
- GB268
- Volunteers
- 330 people
- Sponsor
- Genor Biopharma Co., Ltd.
Arthritis, Cancer
Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction
Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events (irAEs) from rhumatologic, endocrinologic, cardiac or other system origin.
- Conditions
- Arthritis, Cancer, Cardiac Disease, Endocrine System Diseases
- Trial name
- CHIMeRA (NCT03492242)
- Testing
- Immune checkpoint inhibitor
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Psoriasis
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
The purpose of this study is to determine if the use of ustekinumab, followed by abatacept, will prevent relapse in people with moderate to severe plaque psoriasis.
- Trial name
- PAUSE (NCT01999868)
- Testing
- Ustekinumab, Abatacept
- Where
- 10 sites in United States, Canada
- Volunteers
- 108 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunotherapy
Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy
PROMIT is a single arm phase 2 trial evaluating the clinical activity of immune checkpoint blockade (ICB) after administration of dacarbazine (DTIC) in patients with unresectable or metastatic, BRAF wildtype melanoma with primary…
- Trial name
- PROMIT (NCT04225390)
- Testing
- Dacarbazine (DTIC)
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00058279
- Testing
- aldesleukin, ipilimumab
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
This study is a multicenter, open-label, phase II study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104，a PD-1/CTLA-4 bispecific antibody, in…
- Trial name
- NCT05859750
- Testing
- AK104, Gemcitabine, Nab-Paclitaxel
- Where
- 7 sites in China
- Volunteers
- 78 people
- Sponsor
- Akeso
Heptocellular Cancer, Biliary Tract Neoplasms
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Background: Tremelimumab is a cancer treatment drug that helps the immune system recognize and destroy cancer cells. Researchers want to see if it can be used to treat advanced liver cancer.
- Conditions
- Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- NCT01853618
- Testing
- Tremelimumab, RFA, TACE
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Resectable Hepatocellular Carcinoma
Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)
The purpose of this phase Ib/II multicenter randomized control study is to investigate the efficacy and safety of peri-operative treatment with combination of CTLA-4, PD-1 antibodies and bevacizumab in resectable HCC
- Trial name
- NCT07714317
- Testing
- IBI310+ sintilimab + bevacizumab, IBI310+ sintilimab, sintilimab + bevacizumab
- Volunteers
- 90 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR)
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
KEYNOTE-177 is currently the only randomized controlled phase III clinical trial evaluating the efficacy and safety of pembrolizumab versus standard chemotherapy combined with targeted first-line therapy for dMMR/MSI-H metastatic…
- Conditions
- Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H)
- Trial name
- NCT05426005
- Testing
- Cadonilimab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Safety of RG2077 in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune disorder. In this disease, the body's immune system attacks and destroys the cells that cover and protect nerves.
- Trial name
- NCT00076934
- Testing
- RG2077 (CTLA4-IgG4m)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
The purpose of this study is to test the safety of adding a new drug, durvalumab (also called MEDI4736), to chemoradiation with either FOLFOX/Capeox or carboplatin and paclitaxel, following initial chemotherapy with FOLFOX.
- Trial name
- NCT02962063
- Testing
- durvalumab, carboplatin AUC 2/paclitaxel, External beam radiation (EBRT)
- Where
- 7 sites in United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophagogastric Junction/Gastric Adenocarcinoma
A Study on Immunotherapy Combined With Radiotherapy for Esophagogastric Junction/Gastric Adenocarcinoma
A single-arm, prospective phase II clinical study of neoadjuvant PD-1/CTLA-4 combination antibody with low-dose radiotherapy in resectable dMMR/MSI-H esophagogastric junction/gastric adenocarcinoma.
- Trial name
- NCT07053332
- Testing
- PD-1/CTLA-4 combination antibody with low-dose radiotherapy
- Volunteers
- 20 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Rheumatoid Arthritis
Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
The condition that will be studied is Rheumatoid Arthritis (RA), and in particular, RA patients with moderate to highly active disease who were prescribed Abatacept (Orencia®) (ABA) by their physician during their setting of care…
- Trial name
- NCT05782335
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hospital for Special Surgery, New York
Advanced Sarcoma, Metastatic Sarcoma
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
This is a multicenter, open label, Phase 1/2 study of YH001 initially given in combination with envafolimab, and then given in combination with envafolimab plus doxorubicin in patients with advanced or metastatic sarcoma…
- Conditions
- Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma
- Trial name
- NCT05448820
- Testing
- YH001, Envafolimab, Doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Prostate Cancer
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer (HRPC), and to determine the safety and activity profile of a single…
- Trial name
- NCT00050596
- Testing
- MDX-010 / MDX-010 + Docetaxel
- Where
- 11 sites in United States
- Sponsor
- Bristol-Myers Squibb
Head and Neck Squamous Cell Carcinoma
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
Currently, there is a lack of high-quality clinical evidence for subsequent treatment options for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) after first-line treatment, especially for subsequent treatment…
- Trial name
- NCT06494995
- Testing
- Cadonilimab, Low-dose radiotherapy, SBRT
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Advanced Malignant Solid Neoplasm, Anal Carcinoma
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period…
- Conditions
- Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma
- Trial name
- NCT02408861
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 34 sites in United States, Australia
- Volunteers
- 79 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC
The entire treatment process is divided into two phases: Phase I SBRT combined with PD-1/CTLA-4 bispecific antibody (AK104) and Phase II AK104 single-agent maintenance therapy.
- Trial name
- NCT05732662
- Testing
- SBRT, Cadonilimab
- Volunteers
- 25 people
- Sponsor
- The First People's Hospital of Changzhou